

Hybrid capture-based molecular analysis of myeloid malignancies

- **A DNA-based assay** for the detection of point mutations, InDels, and gene fusions
- The hybrid capture-based technology allows the detection of **both common and rare variants**, such as atypical BCR-ABL fusions that are not detectable by FISH
- Evaluation of chromosomal aberrations and copy number alterations available soon*
- User-friendly software for data analysis with links to **relevant annotations, literature and clinical studies**
- Sample material: **blood, bone marrow, tissue (FFPE)**

Panel of tested genes

NEOmyeloid RUO comprises 43 genes known to be altered in myeloid malignancies. Point mutations, small insertions and deletions are detected in 30 genes (shown in italics) and gene fusions in 18 genes (shown in bold).

ABL1	<i>CSF3R</i>	<i>IDH1</i>	<i>NPM1</i>	RUNX1	<i>U2AF1</i>
AF4 (AFF1)	<i>DNMT3A</i>	<i>IDH2</i>	<i>NRAS</i>	RUNX1-T1	<i>WT1</i>
<i>ASXL1</i>	<i>ETNK1</i>	JAK2	PCM1	<i>SETBP1</i>	<i>ZRSR2</i>
<i>BCOR</i>	ETV6	<i>KIT</i>	PDGFRA	<i>SF3B1</i>	
BCR	EVI1 (MECOM)	<i>KRAS</i>	PDGFRB	<i>SRSF2</i>	
<i>CALR</i>	<i>EZH2</i>	MLL1(KMT2A)	PML	<i>STAG2</i>	
CBFB	FGFR1	<i>MPL</i>	RARA	<i>TET2</i>	
<i>CBL</i>	<i>FLT3</i>	MYH11	RPN1	<i>TP53</i>	


Test range for clinical research

The NEOmyeloid assay allows for analyzing diagnostically and prognostically relevant and predictive genes carrying mutations in acute myeloid leukemias (AML), myeloproliferative neoplasms (MPN) and myelodysplastic syndromes (MDS). This spectrum includes, among others, the following entities:

aCML	atypical chronic myeloid leukemia
CML	chronic myeloid leukemia
CMML	chronic myelomonocytic leukemia
CNL	chronic neutrophilic leukemia
ET	essential thrombocythemia
PV	polycythemia vera
PMF	primary myelofibrosis
RARS	refractory anemia with ringed sideroblasts

Tailored support for efficient cancer diagnostics in your laboratory

NEOonsite – innovative molecular cancer profiling



All hybrid capture-based assays can be performed on the NEOonsite platform:

NEOmyeloid RUO – Analysis of myeloid disorders
NEOplus RUO – TMB assessment
NEOselect – Analysis of solid tumors
NEOliquid – Liquid Biopsy Assay

Innovative hybrid-capture NGS technology
for comprehensive and reliable results

Bioinformatic analysis with **full control on all raw and analysis files**

Comprehensive data evaluation and interpretation with the **user-friendly software NEOdiagnosis**